Evidence map›Paper›PMID 37194276›Full record

ArticleJournal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners2024

Oncology pharmacy practice in the United States: Results of a comprehensive, nationwide survey.

Shawn P Griffin, Jessie R Signorelli, Aubrey Lasko, Benjamin J Andrick, David Doan, Shannon Hough, Grazyna Riebandt, Stephen Harnicar

Abstract read
In one paragraph

Article in Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Managing adherence, exposure, and toxicity in oral anticancer therapies.Journal of pharmaceutical health care and sciences · 2025
    Review
  2. Real world practices of luspatercept at an academic medical center.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shawn P GriffinDepartment of Clinical Pharmacy Practice, School of Pharmacy & Pharmaceutical Sciences, University of California, Irvine, CA, USA.ORCID 0000-0002-3818-2490
Jessie R SignorelliDepartment of Pharmacy, Massachusetts General Hospital, Boston, MA, USA.ORCID 0000-0003-2881-3452
Aubrey LaskoDepartment of Pharmacy, Massachusetts General Hospital, Boston, MA, USA.
Benjamin J AndrickEnterprise Pharmacy, Center for Pharmacy Innovations & Outcomes, Danville, PA, USA.
David DoanDepartment of Pharmacy, MD Anderson Cancer Center, Houston, TX, USA.
Shannon HoughMcKesson, Ann Arbor, MI, USA.ORCID 0000-0001-9201-0756
Grazyna RiebandtDepartment of Pharmacy, Clinical Pharmacy Services, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Stephen HarnicarDepartment of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Pharmaceutical ServicesPharmacyHumansMedical OncologyPharmacistsSurveys and QuestionnairesUnited StatesASHP practice advancement initiativeclinical pharmacistmetricsOncology pharmacistsoutcomesworkforce

Identifiers

PMID37194276
PMCPMC10943602

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.